SCHEMBL15768495

SCHEMBL15768495

COC(=O)C1(C)CCC(C)=C(C)C1

nearest known ligand 0.35

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17106402 1.00 MEN1 (0.35) MEN1KMT2ANPSR1LMNASMN1; SMN2
SCHEMBL17106322 0.78 FFAR3 (0.32)
SCHEMBL15785692 0.78 FFAR3 (0.32)
SCHEMBL17131051 0.78 FFAR3 (0.48)
SCHEMBL4486583 0.77 NPSR1 (0.33) MEN1KMT2ANPSR1LMNASMN1; SMN2
SCHEMBL17130784 0.77
SCHEMBL17106385 0.77
SCHEMBL11338238 0.76 FFAR3 (0.31)
SCHEMBL17131052 0.75
Formaldehyde SCHEMBL17106253 0.74 FFAR3 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3521409-A2 PERFUME SYSTEMS The Procter & Gamble Company (US) 2019-08-07 EP disclosed
EP-3521409-A2 PERFUME SYSTEMS The Procter & Gamble Company (US) 2019-08-07 EP disclosed
EP-3122847-B1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2019-05-15 EP disclosed
EP-2928996-B1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2018-04-11 EP disclosed
EP-2928997-B1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2017-01-25 EP disclosed
EP-2928997-B1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2017-01-25 EP disclosed
US-20160289593-A1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2016-10-06 US disclosed
US-20160289593-A1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2016-10-06 US disclosed
US-9303232-B2 Perfume systems THE PROCTER & GAMBLE COMPANY (US) 2016-04-05 US disclosed
US-9303232-B2 Perfume systems THE PROCTER & GAMBLE COMPANY (US) 2016-04-05 US disclosed
US-20150267143-A1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2015-09-24 US disclosed
US-20150267143-A1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2015-09-24 US disclosed
US-20140161740-A1 PERFUME SYSTEMS THE PROCTER & GAMBLE COMPANY (US) 2014-06-12 US disclosed
US-20140161741-A1 PERFUME SYSTEMS THE PROCTER & GAMBLE COMPANY (US) 2014-06-12 US disclosed
US-20140161741-A1 PERFUME SYSTEMS THE PROCTER & GAMBLE COMPANY (US) 2014-06-12 US disclosed
US-20140161740-A1 PERFUME SYSTEMS THE PROCTER & GAMBLE COMPANY (US) 2014-06-12 US disclosed
WO-2014089254-A1 PERFUME SYSTEMS THE PROCTER & GAMBLE COMPANY (US) 2014-06-12 WO disclosed
WO-2014089253-A1 PERFUME SYSTEMS THE PROCTER & GAMBLE COMPANY (US) 2014-06-12 WO disclosed
WO-2014089254-A1 PERFUME SYSTEMS THE PROCTER & GAMBLE COMPANY (US) 2014-06-12 WO disclosed
WO-2014089253-A1 PERFUME SYSTEMS THE PROCTER & GAMBLE COMPANY (US) 2014-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160289593-A1 PERFUME SYSTEMS TRPA1, PORCN, PLIN5 MEN1 3884/4885KMT2A 4669/4885NPSR1 546/4885
US-20150267143-A1 PERFUME SYSTEMS TRPA1, PORCN, PLIN5 MEN1 3884/4885KMT2A 4669/4885NPSR1 546/4885
US-20140161741-A1 PERFUME SYSTEMS TRPA1, PORCN, PLIN5 MEN1 3884/4885KMT2A 4669/4885NPSR1 546/4885
US-20140161740-A1 PERFUME SYSTEMS TRPA1, PORCN, PLIN5 MEN1 3884/4885KMT2A 4669/4885NPSR1 546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.